Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    SAGE 718

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sage Therapeutics Announces Phase 2 Results for Dalzanemdor
    Sage Therapeutics Announces Phase 2 Results for Dalzanemdor

    20 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241119012801/en

    BUSINESSWIRE
    20 Nov 2024
    Share Share
    Sage Therapeutics scraps Alzheimer’s drug after trial fails
    Sage Therapeutics scraps Alzheimer’s drug after trial fails

    09 Oct 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/sage-therapeutics-discontinue-development-alzheimers-drug-2024-10-08/

    REUTERS
    09 Oct 2024
    Share Share
    Sage's dalzanemdor trial design leaves efficacy question unclear
    Sage's dalzanemdor trial design leaves efficacy question unclear

    11 Jun 2024

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/design-huntingtons-trial-means-sage-no-closer-proving-dalzanemdors-efficacy

    James Waldron FIERCE BIOTECH
    11 Jun 2024
    Share Share
    Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
    Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop

    18 Apr 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/sage-therapeutics-scraps-parkinsons-drug-development-after-treatment-fails-mid-2024-04-17/

    REUTERS
    18 Apr 2024
    Share Share